Iris Pharma and RxGen Announce Strategic Alliance
Iris Pharma and RxGen Partner to Deliver Seamless and Superior Drug & Medical Devices Development Services in Ophthalmology
Iris Pharma , a leading ophthalmic preclinical and clinical contract research organization (CRO), and RxGen , a specialty preclinical CRO focused on the development and application of translational research models, have established a Strategic Alliance to offer fully integrated “bench-to-bedside” ophthalmology research services to the global pharmaceutical and biotechnology industries.
Under the newly forged transatlantic alliance, Iris Pharma can offer immediate access to RxGen’s nonhuman primate ophthalmic research models and related preclinical in vivo services, via a flexible engagement model, that allows customers to benefit from the combined preclinical and clinical insight, capabilities, and expertise that RxGen and Iris Pharma collectively represent.
“Our alliance with RxGen is an exciting development for both companies. For Iris Pharma, this relationship allows us to add RxGen’s unique capabilities and expertise to our existing portfolio of research and development services, completing the full value-chain required to bring a drug from bench to bedside”, said Pierre-Paul Elena, CEO of Iris Pharma.
“The ability to offer integrated packages of services and a comprehensive and seamless program of preclinical and clinical drug development will improve our competitive position in the marketplace and generate significant value for our clients”, said Yann Quentric, Head, Business Development & Marketing of Iris Pharma.
“Effectively translating discovery to approved therapeutic demands time and cost efficient program design and management, capitalizing on the best available preclinical test systems while maintaining a clear eye on the clinical pathway”, said Matthew Lawrence, CEO of RxGen. “We look forward to working with Iris Pharma to match capabilities with needs to provide the lowest risk, highest return translational research solutions.”
“We are pleased to enter into an alliance with Iris Pharma, as we share a similar commitment to values critical to advancing Sponsor programs; scientific integrity, collaborative engagement and superior service”, said Christopher Stanley, Chief Business Officer of RxGen. “The unique combination of RxGen’s in vivo ophthalmic capabilities in nonhuman primates and Iris Pharma’s world leading position in ophthalmology uniquely positions us to provide superior innovative and adaptive services that will speed time to market for our customers”.
About Iris Pharma : Iris Pharma is an independent CRO specializing in preclinical and clinical research services in ophthalmology. Founded in 1989 by Dr Pierre-Paul Elena, Iris Pharma offers expertise in the development of ophthalmic drugs and ocular medical devices to the pharmaceutical industry and biotechnology companies worldwide. Iris Pharma services include proof of concept and GLP-compliant preclinical studies (safety, tolerance, pharmacokinetics, efficacy), bioanalysis, preclinical formulation, clinical trials and consulting services. Iris Pharma’s research facilities are GLP compliant.
For more information, please visit www.iris-pharma.com.
About RxGen: RxGen, Inc. is a specialty preclinical CRO, providing innovative in vivo disease modeling and related preclinical research and development services to meet translational research needs of the global pharmaceutical and biotechnology industries. RxGen accelerates therapeutic and medical technology evaluation by the application of in vivo disease modeling and pharmacokinetic, pharmacodynamics and safety assessments, with deep therapeutic domain expertise in ophthalmology, central nervous system, metabolic and cardiac diseases and disorders. RxGen’s research facilities are AAALAC accredited and GLP compliant, supporting a range of services, from proof-of-concept through IND-enabling / regulatory studies.
For more information, please visit www.rx-gen.com .
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50243318&lang=en
Contact:
RxGen Contact:
Chief Business Officer
Christopher
Stanley, (203) 498-9706
cstanley@rx-gen.com
or
Iris
Pharma Contact:
Head, Business Development
Yann Quentric,
+33 4 93 59 49 59
y.quentric@iris-pharma.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Equiduct Expands into the Swiss Market15.5.2025 08:00:00 CEST | Press release
Equiduct, the leading pan-European retail-focused exchange, today announced the launch of its Swiss equity segment, providing retail brokers using Apex with access to 138 of the most liquid Swiss-listed stocks — all priced in Swiss francs (CHF). The newly available securities include heavily traded household names such as Nestlé S.A., Novartis AG, UBS Group AG, and ABB Ltd. Liquidity on the Swiss segment of Equiduct is supported by Apex market makers Virtu Financial, Hudson River Trading, and Optiver. As with all executions on Equiduct, trades on the Swiss segment will benefit from fully interoperable clearing via Equiduct’s pan-European network of CCPs: LCH Ltd, Cboe Clear, and the local Swiss CCP SIX x-clear. This expansion follows formal approval from the Swiss Financial Market Supervisory Authority (FINMA), which recognises Börse Berlin and Equiduct as a regulated market under Article 41 of FinfraG. This status also paves the way for Swiss banks and brokers to join Equiduct as dire
Allianz Reports Record Operating Profit and Is Fully on Track to Achieve Full-Year Outlook15.5.2025 07:26:00 CEST | Press release
May 15, 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514121549/en/ Oliver Bäte, Chief Executive Officer of Allianz SE (Photo: Allianz SE) 1Q 2025 Total business volume advances 11.71 percent to 54.0 billion euros reflecting sustained momentum across all segments Operating profit increases 6.3 percent to 4.2 billion euros, reaching 26 percent of our full-year outlook midpoint Shareholders’ core net income is stable at a very good level of 2.6 billion euros. Adjusted for a one-off tax provision related to the forthcoming sale of our stake in our Indian Joint Ventures, shareholders’ core net income is up 5 percent Core earnings per share grow 2.9 percent and reach 6.61 euros. Adjusted for the above-mentioned one-off tax provision, core earnings per share are up 7 percent Annualized core RoE is robust at 16.6 percent, or 17.2 percent adjusted for the effect of the one-off tax provision Solvency II capitalization ratio
Corona Global Named Most Valuable Beer Brand in Kantar BrandZ Rankings for Second Consecutive Year15.5.2025 06:01:00 CEST | Press release
Michelob ULTRA Moves Into Top 5 Most Valuable Beer Brands GloballyAB InBev Brands Represent 8 of the Top 10 Most Valuable Beer Brands Globally Corona has been recognized as the most valuable beer brand in the world for the second consecutive year in Kantar's BrandZ 2025 Most Valuable Global Brands report, released today. Eight out of the 10 most valuable global beer brands belong to AB InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD), according to the report ranking the top brands in the world. In 2024 AB InBev produced all-time high revenue and 15% Underlying EPS growth. The year marked double-digit growth for Corona outside of its home market of Mexico and triple-digit growth of its no-alcohol brand Corona Cero. Corona Cero is the first beer brand to sponsor the Olympic Games making its debut in Paris 2024. In 2025, Corona is celebrating its 100-year anniversary with events all over the world through its “Corona 100” platform. Corona is followed by Budweiser, the second most valuab
Forrester Opens Nominations For Its 2025 B2B Awards In EMEA And APAC15.5.2025 06:00:00 CEST | Press release
Awards honor B2B organizations that drive revenue growth through effective alignment of marketing, sales, and product strategies Forrester (Nasdaq: FORR) today opened calls for nominations for its 2025 B2B Return On Integration Honors and B2B Programs Of The Year Awards in Asia Pacific (APAC) and Europe, Middle East, and Africa (EMEA). These awards will recognize B2B organizations based in both regions for achieving functional excellence and outstanding alignment across marketing, sales, and product — the B2B revenue engine — to improve customer experience and drive growth. Nominations for both award categories are open to organizations of all sizes in each region. B2B leaders across APAC and EMEA — including chief marketing officers, chief sales officers, chief product officers, and other marketing, sales, and product leaders — are invited and encouraged to apply. To be eligible, programs need to be developed by leaders and teams based in the APAC or EMEA regions. The nomination crite
Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 04:12:00 CEST | Press release
Results at a glance:71.4% of MetaXplore™ reports from 4,616 patients identified actionable results41.9% tested positive for abnormal microbiome markers linked to gastrointestinal health9.9% tested positive for gastrointestinal markers, including inflammation, pancreatic insufficiency, or blood in stool19.6% of reports tested positive for multiple markers (microbiome and gastrointestinal)65% of patients reported health improvements following clinician-directed recommendations informed by MetaXplore Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often g
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom